Citi analyst Yigal Nochomovitz raised the firm’s price target on Apellis Pharmaceuticals to $91 from $86 and keeps a Buy rating on the shares following the approval of Syfovre. The FDA letter reflects a broad label, supporting both foveal/extra-foveal and monthly/every-other-month regimens, the analyst tells investors in a research note. The firm says Apellis remains its top pick.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- Apellis rally on approval ‘might fade,’ says Wells Fargo
- Iveric now has ‘clearer path towards approval,’ says BofA
- FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
- Apellis says FDA approves SYFOVRE for GA treatment